IN2014DN05972A - - Google Patents

Info

Publication number
IN2014DN05972A
IN2014DN05972A IN5972DEN2014A IN2014DN05972A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A IN 5972DEN2014 A IN5972DEN2014 A IN 5972DEN2014A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A
Authority
IN
India
Prior art keywords
diseases associated
present
glucose metabolism
therapeutic agent
abnormal glucose
Prior art date
Application number
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of IN2014DN05972A publication Critical patent/IN2014DN05972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism which comprises a 2 phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
IN5972DEN2014 2012-01-27 2013-01-25 IN2014DN05972A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (en) 2012-01-27 2013-01-25 Therapeutic agent for diabetes

Publications (1)

Publication Number Publication Date
IN2014DN05972A true IN2014DN05972A (en) 2015-06-26

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5972DEN2014 IN2014DN05972A (en) 2012-01-27 2013-01-25

Country Status (15)

Country Link
US (1) US20150005506A1 (en)
EP (1) EP2808018B1 (en)
JP (1) JP5924699B2 (en)
KR (1) KR20140134266A (en)
CN (1) CN104066430A (en)
AR (1) AR089812A1 (en)
AU (1) AU2013212865A1 (en)
BR (1) BR112014017902A2 (en)
CA (1) CA2862602A1 (en)
HK (1) HK1201209A1 (en)
IN (1) IN2014DN05972A (en)
MX (1) MX2014008484A (en)
RU (1) RU2014134845A (en)
TW (1) TW201334779A (en)
WO (1) WO2013111870A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628671B (en) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 Containing oil of mirbane thiazole carboxylic acid amides compounds and the purposes of benzene carbon amidine structure
CN104610188B (en) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 Itrile group benzene thiazole carboxylic acid amides's compounds containing benzene carbon amidine structure, its preparation and purposes
CN104610190B (en) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 One class contains halogenophenyl thiazole carboxylic acid amides's compounds and the purposes of cyclopropyl amidine structure
CN104628673A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Nitrile benzene thiazolecarboxamide type compound containing tert-butylamidine structure and application thereof
CN104628672A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Alkoxyphenylthiazole carboxylic acid amide compounds containing phenylamidine structures and application
KR102473677B1 (en) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 Liquid crystal display
CN109069490B (en) 2016-02-19 2021-07-16 上海根乃津药业科技有限公司 Dementia treatment or preventive medicine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000051I1 (en) * 1990-11-30 2009-02-05 Teijin Ltd 2-ARYLTHIAZOL DERIVATIVE AND MEDICAMENT CONTAINING THEREOF
HUP9902721A2 (en) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Concentrated fabric softening composition and highly unsaturated fabric softener compound therefor
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2006012438A2 (en) * 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
AU2006276933A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
WO2007019153A2 (en) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
EP1957064A4 (en) * 2005-11-21 2010-01-06 Tap Pharmaceutical Prod Inc Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (en) * 2006-02-13 2007-08-23 Hiroshima Univ Glucose intolerance, type II diabetes, hyperlipidemia, metabolic syndrome, visceral fat obesity, fatty liver or non-alcoholic steatohepatitis
BRPI0718611A2 (en) 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc METHODS FOR PRESERVING RENAL FUNCTION USING XANTINE OXIDOREDUTASE INHIBITORS.
DK2217577T3 (en) * 2007-11-27 2014-10-20 Ardea Biosciences Inc HIS UNKNOWN RELATIONSHIPS AND PREPARATIONS AND PROCEDURES FOR USE THEREOF
JP5314123B2 (en) * 2008-03-31 2013-10-16 シー アンド シー リサーチ ラボラトリーズ Heterocyclic derivatives
US8410154B2 (en) * 2008-04-30 2013-04-02 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
JP5820269B2 (en) * 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Method for treating hyperuricemia using SGLT2 inhibitor and composition containing SGLT2 inhibitor
EP2398319A4 (en) * 2008-10-19 2012-11-14 Richard J Johnson Therapeutic compositions and methods for treating chronic kidney disease associated with a metabolic imbalance
WO2011022757A1 (en) * 2009-08-24 2011-03-03 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
RU2602188C2 (en) * 2010-06-16 2016-11-10 Такеда Фармасьютикалз Ю.Эс.Эй.,Инк. Modified release pharmaceutical composition containing febuxostat
AR082022A1 (en) * 2010-06-25 2012-11-07 Teijin Pharma Ltd THERAPEUTIC AGENT OF SUSTAINED LIBERATION FOR HYPERTENSION AND RENAL DYSFUNCTION

Also Published As

Publication number Publication date
HK1201209A1 (en) 2015-08-28
WO2013111870A1 (en) 2013-08-01
EP2808018A4 (en) 2015-07-15
AR089812A1 (en) 2014-09-17
AU2013212865A1 (en) 2014-08-14
KR20140134266A (en) 2014-11-21
MX2014008484A (en) 2014-10-14
JPWO2013111870A1 (en) 2015-05-11
TW201334779A (en) 2013-09-01
US20150005506A1 (en) 2015-01-01
CN104066430A (en) 2014-09-24
JP5924699B2 (en) 2016-05-25
BR112014017902A2 (en) 2017-08-22
EP2808018B1 (en) 2018-03-14
RU2014134845A (en) 2016-03-20
CA2862602A1 (en) 2013-08-01
EP2808018A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
MX2015003594A (en) Therapeutic or prophylactic agent for tumor lysis syndrome.
IN2015MN00404A (en)
MY183312A (en) Pharmaceutical formulation
AU2012214029A8 (en) Rorgammat inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015017861A (en) Benzothiophene derivatives as estrogen receptor inhibitors.
PH12015502839B1 (en) Antiviral compounds
MX361653B (en) Process for preparing bile acid derivatives.
PH12017501426A1 (en) Derivatives of betulin
IN2015DN00185A (en)
JO3530B1 (en) 1,4-disubstituted pyridazine analogs there of and methods for treating smn-deficiency-related conditions
MX2015010971A (en) Novel pyrazole derivative.
IN2014MN02106A (en)
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
IN2014DN05972A (en)
MY187718A (en) Pharmaceutical formulations
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX364400B (en) Tetracycline compounds.
WO2011159124A3 (en) Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same
PH12014500065A1 (en) A new therapeutical composition containing apomorphine as active ingredient
WO2011123536A8 (en) Polycyclic tetracycline compounds
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014CN04449A (en)
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids